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Alpha 1- antitrypsin (α1AT) a 54 kDa glycoprotein is a protease inhibitor. In the
absence of α1AT, elastase released by lung macrophages, was not inhibited and lead
to elastin breakdown and pulmonary problems such as emphysema or COPD. α1AT
has three site of N-glycosylation and a characteristic reactive central loop (RCL). As
small-scale medicines are preferred for pulmonary drug delivery, in this study α1ATs
(1, 2, 3, 4 and 5) were engineered and shortened from the N-terminal region. In
order to investigate the effect of different mutations and the deletion of 46 amino
acids theoretical studies were performed. Homology modeling was performed to
generate the 3D structure of α1ATs. The 10 ns Molecular Dynamic (MD) simulations
were carried out to refine the models. Results from MD and protein docking showed
that α1AT2 has the highest binding affinity for neutrophil elastase, provided the basis
for the experimental phase in which sequences from the five α1AT constructs were
inserted into the expression vector pGAPZα and expressed in the yeast Pichia
pastoris. Although, the α1AT2 construct has the highest inhibitory activity even more
that the native construct (α1AT5), results indicated the presence of protease
inhibitory function of all the proteins' construct against elastase.
Keywords: Alpha 1- antitrypsin, Molecular dynamics (MD) simulation, Neutrophil
elastase, Protein dockingIntroduction
α1AT is a 54 kDa glycoprotein which is a serine protease and broad group of other
protease inhibitor. This protein protect the lung from cellular inflammatory enzymes,
especially neutrophil (leukocyte) elastase, therefore it is called human neutrophil elas-
tase inhibitor [1-3]. In the absence of α1AT, elastase released from neutrophils, was
not inhibited and lead to elastin breakdown and other symptoms like pulmonary
problems such as emphysema or COPD in adults [2,3]. Impaired α1AT secretion in
liver and accumulation in liver cells also cause cirrhosis in neonatal [4]. Relation between
α1AT and numbers of diseases including asthma, rheumatoid arthritis, anterior uveitis
and systemic lupus erythematosus suggest that α1AT is not only an anti- inflammation
protein but also an immune system regulator [5-8]. α1AT regulates lymphocyte© 2013 Pirooznia et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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is suggested as an antiapoptotic factor in lung epithelial cells [9]. Besides it was illustrated
that protease-antiprotease imbalance is an important factor in COPD and other pulmo-
nary diseases pathogenesis such as bronchitis. In this process exogenous proteolytic en-
zymes leads to lung breakdown (because human neutrophil elastase cannot be inhibited
by α1AT) [10]. Cigarette smoking is considered as the main cause of COPD which is
the fourth leading cause of death in the United States [2]. The oxidation of Met358
in the reactive center loop (RCL) of α1AT leads to a critical decrease in inhibitory
capacity of this protein against elastase which cause inactivation in protective func-
tion of this protein [11]. It was shown that oxidation sensitivity is a regulatory
process, and α1AT inactivation possibly causing lung tissue breakdown in inflamma-
tory site through oxygen radicals released from phagocytes. Therefore, smoking
causes oxidation of critical residues (methionine) in α1AT and inactivates this pro-
tein. α1AT resistant to oxidation can improve health conditions in COPD patients
and also reduction of apoptosis induced by cigarette smoking in vitro. α1AT beside
antiapoptotic function in in vitro, has broad anti inflammatory effects in human.
Therefore treatment of CF patients with aerosolized α1AT has been shown to reduce
sputum neutrophil numbers, IL-8 concentration and elastase function. The effect of
α1AT on IL-8 as a neutrophil-chemoattractant and neutrophil recruitment to lung is
also important because neutrophils are considered as the main cause of COPD
pathogenesis and clinical effects of α1AT in COPD are obvious [7].
Nowadays the only intravenous infusion of α1AT is available in the world as thera-
peutic agent which is not the first choice for COPD treatment due to its high cost and
low availability [12]. But the aerosol form of α1AT in CF and COPD patients for the
prevention of disease progression is not hard to believe [13].
α1AT in its mature has a polypeptide chain consisting of one cystine, two trypto-
phans and nine methionine residues. α1AT has three site of N-glycosylation which
are highly mannosylated because tri- and tetra N-glycans can be attached to aspargine
107 [1].
The oxidation of Met358 in the reactive center loop (RCL) of α1AT leads to a critical
decrease in inhibitory capacity of this protein against elastase which cause inactivation
in protective function of this protein. It was shown that oxidation sensitivity is a regula-
tory process, and α1AT inactivation possibly causing lung tissue breakdown in inflam-
matory site through oxygen radicals released from phagocytes [14,15].
Several mutations within the α1AT genes have been found with the most common
point mutations including S and Z mutations with Glu264Val and Glu342Lys substitu-
tions, respectively [16]. FDA has confirmed the utilization of four human plasma de-
rived products of α1AT-Prolastin, Zemaira, Aralast and Glassia as replacement or
augmentation therapy. These products which increase the intravenous concentration of
α1AT, cost more than 100000$ for each person annually. The infusion form of α1AT
has several disadvantages such as: because it has blood origin the risk of viral and non
viral contamination is high, also due to the limitation of proteins extracted from blood,
huge production is not possible [10,12,17].
The aerosolized α1AT are under study. In the aerosol form, 25%-45% of aerosolized
particle reach the respiratory system but in intravenous infusion only 10%-15% of
α1AT reach to this site. The aerosolized α1AT not only affect locally its main site of
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therefore depress immune response reactions because of long-term use of α1AT [18].
In the other hand, yeasts are effective eukaryotic systems in recombinant protein syn-
thesis in large scale and are able to perform post translational modifications such as
glycosylation. In spite of the useful properties of yeasts, these cells are not effective
enough for the secretion of high molecular weight glycoproteins [19-22]. Therefore any
modification which possibly increases the efficacy and secretion of high molecular
weight glycoproteins in yeast can have significant results in protein based medicine
products in these cells. With the reduction in size of α1AT beside the preservation of
function in production process and increase in the secretion ability of yeast, alteration
in glycosylation patterns and elimination of some carbohydrate chains reduce the im-
munogenicity of secreted α1AT, as a yeast characteristic property is addition of huge
mannosylation patterns to secreted proteins.
Huge mannosylation pattern in yeast increases the molecular weight significantly,
possibly affects protein activity and also causes difficulty and disturbance in drug de-
liver to the lung.
Therefore, charbohydrate chains deletion from recombinant α1AT are in the majority
of this project. Then, protein length from N-terminal was reduced to produce a smaller
molecule which has the same and even higher inhibitory activity as the native α1AT.
So, a new α1AT structures were obtained that can be appropriate candidates for pul-
monary drug delivery. Therefore, five different α1AT structures with different glycosyla-
tion patterns and molecular weights were constructed base of theoretical studies.
Beside, each α1AT structures were subjected to three or five different site directed mu-
tagenesis at the same time for both thermal and oxidative inactivation stability. Inhibi-
tory properties of each α1AT constructs were investigated through Elastase Inhibitory
Concentration (EIC). Previous studies have shown that the two methionine residues
351 and 358, and in sever conditions methionine 226 are susceptible to oxidation. Oxi-
dation of methionine 358 leads the loss of anti-elastase activity of α1AT. The other me-
thionine residue (Met351) is also as susceptible to oxidation and anti-elastase activity
loss as Met358 [23,24].
In this study, site directed mutations in α1AT, produce an active, lower molecular
weight, resistant to oxidation and thermal inactivation, with an appropriate half life and
unglycosylated protein in Pichia Pastoris as a host. In this study we showed that muta-
tions and engineering of the protein molecule, lead to an improvement in inhibitory
function. Furthermore, a protein with a less molecular weight and immunogenicity
which is suitable for drug packaging and targeting to the lung which is the site of
α1AT's action was produce. Molecular dynamic studies showed that deletion of the
first alpha-helix from N-terminal sequence have no effect on α1AT inhibitory func-
tion. Therefore a reduction of 7 kDa in molecular weight of α1AT, 5 kDa contribu-




Five different protein sequences of α1AT namely α1AT1, α1AT2, α1AT3, α1AT4 and α1AT5
were selected (Table 1). Homology modeling of α1AT subtypes was performed using as







α1AT1 350 39342.3 M351V, M358L, M226L 46 aa
α1AT2 396 44560.8 M351V, M358L, M226L, N83Q, N243Q _
α1AT3 350 39328.2 M351V, M358L, M226L 46 aa
α1AT4 396 44560.8 M351V, M358L, M226L, N46Q, N243Q _
α1AT5 396 44532.8 M351V, M358L, M226L _
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file 1QLP. I-TASSER server was applied for the model construction. Structures with the
lowest objective function were used for performing molecular dynamic simulation [25].
Molecular dynamics simulations
The MD simulations were carried out for 10 ns using GROMACS 4.5.3 software pack-
age with the standard GROMOS43a1 force field in the presence of explicit solvent mo-
lecules and Na counterions [26,27].
The energy of these systems was minimized using the steepest descent approach
realized in the GROMACS package to remove close Van der Waals contacts and to
allow formation of hydrogen bonds between water molecules in the periodic box
and the protein. A 100 ps MD simulations were performed at the canonical ensem-
ble (NVT) and the temperature was increased from 200 to 300 K. The simulations
were continued for another 100 ps at the isobaric-isothermal ensemble (NPT) so
that the systems reached equilibration at a constant pressure. The density was sta-
bilized around 0.98 g/cm3 during equilibration phase in constant pressure. Finally,
a 10 ns MD simulations were performed at the NPT canonical ensemble and the
periodic boundary conditions were used in all three dimensions. NVT ensemble
simulation was carried out using TIP3P as water models. In all simulations, to keep
all hydrogen bonds rigid the SHAKE algorithm was used. The mesh Ewald (PME)
summation technique was used to calculate long-range electrostatics interactions; a
14A˚ cutoff for van der Walls interactions, a 12A˚ cutoff for Coulomb interaction
with updates every 10 steps, where a time step of 2 fs was considered. In all simu-
lations, the SHAKE algorithm was used to fix hydrogen bond trembling with other
atoms. MD simulations were performed in water in a cubic box and 8A° water layer
thickness was considered.
Analyses of RMSD, RMSF, solvent accessible surface area, gyration radius, secondary
structure, number of hydrogen bonds and dihedral-angle structural distance maps have
been carried out using the GROMACS 4.5.3 analysis tools. The first 5 ns of simulation
time were discarded to take into account the long system equilibration and all the ana-
lyses have been performed on the last 5 ns.
Molecular docking
The calculations regarding the interaction between neutrophil elastase and α1AT struc-
tures, which were obtained by MD simulations, were performed using 3D-Dock pro-
gram. The structure of neutrophil elastase was obtained from the Protein Data Bank
(PDB ID: 2D26). Protein dockings were carried out using MultiDock software package.
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of α1ATs were considered as 1.3 Å, and the RPScore program was used to score all
known complexes. For each calculation, 100 complexes with the highest score were se-
lected using the MultiDock program. Finally, the complexes at the lowest energy levels
were selected and compared with each other.
Bacteria and P. pastoris strains and media
The E. coli strain DH5α was used for propagation of recombinant plasmids. The P. pastoris
strain X-33 (Invitrogen) was used as a host for the protein expression. Recombinant bac-
teria were cultured in low salt LB broth medium (0.5% (w/v) yeast extract, 1% (w/v)
tryptone, 0.5% (w/v) NaCl) supplemented with 25 μg ml-1 of zeocin (Invitrogen). P. pastoris
was cultured on the following medium: YPDS plates (1% (w/v) yeast extract, 2% (w/v) pep-
tone, 2% (w/v) dextrose, 1 M sorbitol, and 1.5% (w/v) bacteriological agar) supplemented
with 100 μg/ml of zeocin.
Cloning of α1AT in pGAPZαA plasmid
For the construction of the expression vector EcoRI and XbaI sites were introduced re-
spectively at the 5' and 3' end of α1ATs by PCR with specific primers (Table 2). Using
DNA from the previous work as template, the resulting 1059 and 1197 bp PCR product
was cloned into the pGAPZαA plasmid (Invitrogen, USA).
P. pastoris transformation and selection
P. pastoris cells were grown overnight in YPD broth (at 28°C/250 rpm) and prepared for
transformation according to the manufacturer’s recommendations (Invitrogen). The re-
combinant plasmid was linearized with BspHI in the GAP promoter region and
electrotransformed into P. pastoris X33 electrocompetent cells using a Bio-Rad genepulser
apparatus (at 1.5 kV, 25 F, 400Ω and 8 ms). Zeocin resistant transformants were selected
on YPDS agar plates. P. pastoris X33 with empty vector was transformed for negative
control tests. Integration analysis was confirmed by PCR following with the primers
pGAP forward and 3'AOX1 reverse. Correct integration will result in the formation
of ~1050-1200 bp PCR products.
Small scale protein expression
The clones that have given a PCR product of the correct size were used to produce
medium-scale cultures. Samples were taken every 24 hours for supernatant analysis.
Culture medium was collected after 3 days culture in 250 ml of YPD at 28°C, byTable 2 Primer sequences
Name Sequence Mer
α1AT-Forward (5'-AAAGAATTCGAGGATCCCCAGGGAGATGC-3') 29
α1AT-Reverse (5'- TTTTCTAGAGCTTATTTTTGGGTGGATTCACCAC-3') 34
Tα1AT-Forward (5'- AAAGAATTCAGCACCAATATCTTCTTCTC-3’) 29
Tα1AT-Reverse (5'- TTTTCTAGAGCTTATTTTTGGGTGGATTCACCAC-3') 34
pGAP –Forward (5´-GTCCCTATTTCAATCAATTGAA-3´) 22
3́ AOX1 (5´-GCAAATGGCATTCTGACATCC-3´) 21
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culture supernatant was determined by SDS PAGE, followed by Coomasie staining
and Western Blot.
Large scale protein expression
To obtain large quantities of α1AT fermentation was performed in a 5 L fermentor with a
4 L working volume YPD medium was initially used as the growth medium for α1AT ex-
pression. To improve the growth characteristics of the cells in scaled-up fermentation, dif-
ferent media including YPD, YPG and YNB were examined, considering the salts and
source of carbon. The rate of air supply and agitation was chosen as high as possible.
Therefore, air was supplied at a rate of 10 l/min and the agitation rate was set at 400 rpm
under this scale.
SDS-PAGE and silver staining
The cells were removed and the supernatant was precipitated by using 100% Aceton so-
lution. After drying, the pellet was resuspended in loading buffer (10% w/v SDS, 10 nM
β-mercaptoethanol, 20% v/v Glycerol, 0.2 M Tris–HCl, pH 6.8, 0.05% Bromophenol
blue w/v), heated for 10 min, in boiling water and electrophoresed at 12% SDS-
PAGE/100 V along with molecular weight marker (Fermentas). Gel was stained with
silver nitrate according to Celis and coworkers [28].
Western blot analysis
Protein samples resolved on SDS-PAGE, were electro-blotted to Polyvinylidene Difluoride
(PVDF) membrane (Millipore) in transferring buffer (0.025 M Tris, 0.19 M glycine,
and 20% (v/v) methanol) overnight at 20 V/4°C. The membrane was treated with
PBS-T-BSA (PBS, 0.1% (v/v) Tween 20, 1% (w/v) BSA) for 2 hours to block binding
sites. After washing step, membrane was reacted with 1000-fold diluted goat anti-
human alpha-1 antitrypsin polyclonal antibody, conjugated with HRP (Abcam) for
3 hr. To eliminate non specific reactions, a supernatant of non- recombinant X-33
culture treated side by side accordingly as negative control. Subsequently, protein
bands reacted positively, were visualized at the presence of 4-chloro1-naphtol sub-
strate in PBS.
Inhibitory activity assay
Elastase activity was measured by EnzChek® Elastase Assay Kit (Molecular Probes,
Inc.) according to the manufacturer’s recommendations. The EnzChek kit contains
DQ™ elastin soluble bovine neck ligament elastin that has been labeled with
BODIPY® FL dye such that the conjugate’s fluorescence is quenched. The non-
fluorescent substrate can be digested by elastase or other proteases to yield highly
fluorescent fragments. The presence of an inhibitor such as α1AT blocks the sub-
strate digestion hence subsequent fluorescent emission. The resulting change in
fluorescence level was monitored using a standard fluorometer (Hitachi F-3010)
with a maximum absorption at 505 nm and a maximum fluorescence emission at
515 nm. Commercial human α1AT was used as a positive control and the reac-
tion buffer and the supernatant from non-recombinant P. pastoris (X-33 strain)
culture as negative controls.
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Molecular dynamics simulation
The root-mean-square deviation (RMSD)
One of the most frequently used measures of assessing the stability of an MD simula-
tion over the course of time is the RMSD of the backbone atoms relative to the starting
structure during the MD production phase. Although the RMSDs reach a stable value
within the first ns, all the analyses have been carried out discarding the first three
nanoseconds, i.e. over the last seven nanoseconds (Figure 1). This was done to guaran-
tee an investigation over a well thermalized system.Gyration radius
To determine the compactness of the chains during the simulations, the time-dependent
squared radius of gyration, Rg 2 (t) was determined. The radius of gyration gives an esti-
mate of the characteristic volume of a globular polymer, which is inversely related to its
compactness (Figure 2).Secondary structure comparison
The analysis of the secondary structures, carried out with the program DSSP by sam-
pling trajectories every 5 ps. Results indicates that the two proteins have comparable
secondary structure regions. As shown in Table 3 no difference is observed in the struc-
ture of these α1AT mutants (Table 3).Total energy changes
Total energy changes during 10 ns of simulation time at the equilibrium phase under
NPT conditions were carried out for the certitude of simulation stability (Figure 3). AsFigure 1 RMSD value of the backbone atoms of each α1AT structures in respect to the reference
structure (α1AT5, blue) during 10 ns total simulation time.
Figure 2 Radius of gyration as a function of time with respect to the starting structures during the MD
simulations is shown for each α1AT structures in respect to the reference structure (α1AT5, blue).
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pressure conditions after 20 ps for all simulations remains constant.
Temperature and density
The temperature and the densities for all α1ATs were 300 K and 1.00 gr/cm3, respectively
that ultimately became fixed and stable, representing further proof of simulation stability
(Figure 4).
Structural fluctuations
Figure 5 shows the Cα root mean square fluctuations (RMSF) of α1AT structures in
comparison to α1AT structure 5 as a reference. The two α1AT structures 2 and 4 show
fewer fluctuations. As revealed in Figure 5, simulation of five structures indicate that a
large part of residues is characterized by fluctuations not higher than 2.0 Å, apart from
the regions of the C and N-terminal tails. Therefore, the obtained structures from the
simulation were optimal and the different structural regions affected each other. Hence,
in each simulation, systems have reached to equilibrium.Table 3 Secondary structure evolution of the five α1AT structures with simulation time
Secondary structure of α1AT 1 3 5 2 4
β sheet + turn 13.8328 13.8328 13.7837 13.7837 13.7837
Coil 72.6224 72.6224 72.7027 72.7027 72.7027
β sheet 12.1037 12.1037 12.1621 12.1621 12.1621
Bend 11.8155 11.8155 11.6216 11.6216 11.6216
Turn 1.7291 1.7291 1.6216 1.6216 1.6216
3-Helix 1.7291 1.7291 1.8918 1.8918 1.8918
Figure 3 Plots of total energy versus time over the molecular dynamics trajectory for each α1AT
structures in comparison to the reference structure (α1AT5, blue).
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Figure 4 Plot of the system A) density and B) temperature during the 10 ns simulations of
α1AT structures.
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Figure 5 Root mean square fluctuation (RMSF) as a function of residue number for α1AT structures
in respect to the reference structure (α1AT5, blue).
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The accessible surface area (ASA) was computed considering contribution of side chain
atoms and hydrophobic and hydrophilic contributions to the total ASA were calculated
during the simulation time (Figure 6).
Protein docking
In each simulation 100 complexes were made, and complexes with the most
binding affinity, which represent the best interaction in complexes, were selected
(Table 4).Figure 6 Comparison of accessible surface area of neutrophil elastase in the free and
complex form.
Table 4 Docking energy of α1AT structures and neutrophil elastase
Structure Energy value
α1AT1-Neutrophil Elastase Interaction −41.03 Kcal/mol
α1AT2-Neutrophil Elastase Interaction −46.42 Kcal/mol
α1AT3-Neutrophil Elastase Interaction −40.37 Kcal/mol
α1AT4-Neutrophil Elastase Interaction −41.93 Kcal/mol
α1AT5-Neutrophil Elastas Interaction −41.72 Kcal/mol
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Integration analysis
Ten zeocin-resistant colonies of each α1AT structures were selected. The integration of
α1AT gene into the P. pastoris genome is verified by PCR. As shown in Figure 7, PCR
products were separated on a 1% agarose gel and stained with ethidium bromide. All
PCR fragments have the expected ~1600 bp sizes.
SDS page
The culture expressing native and truncated α1AT was harvested at the following time
intervals: 0, 12, 24, 48, 60, 72 and 96 hrs. The supernatant from each culture sample
was examined using SDS-PAGE in order to determine the native and truncated-
engineered α1ATs expression levels. The 72 hrs time period represented the best time
for harvesting in comparison to non-recombinant X-33 culture (Figure 8).
Western blot
To confirm the identity of truncated-engineered proteins, proteins were reacted with
α1AT antibody in a western blot analysis. The recombinant α1AT was identified as two
distinct bands Western blotting using goat polyclonal to alpha-1 antitrypsin for native
and truncated-engineered α1ATs is shown in Figure 8, where the native and engineered
proteins are detected in both Western blots.
Elastase Inhibitory Capacity (EIC)
The inhibitory function of native and truncated α1AT showed no significant difference
and both α1ATs were found to be functional (Figure 9).Discussion
Alpha 1- antitrypsin (α1AT) is a 54 kDa glycoprotein which is a serine protease
and broad group of other protease inhibitor. This glycoprotein contains 394
amino acids and three glycosylation sites. α1AT protect lung from neutrophile
elastase in inflammation or infection therefore it is called neutrophile elastase in-
hibitor [1,17]. The oxidation of Met358 in the RCL leads to a critical decrease in
inhibitory capacity of this protein against elastase which cause inactivation in pro-
tective function of this protein. It was shown that oxidation sensitivity is a regula-
tory process, and α1AT inactivation possibly causing lung tissue breakdown in
inflammatory site through oxygen radicals released from phagocytes. Therefore,
smoking causes oxidation of critical residues (methionine) in α1AT and inactivates
this protein [14,15]. α1AT resistant to oxidation can improve health conditions in
Figure 7 (See legend on next page.)
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Figure 7 PCR colony screening was performed using plasmid-specific primers (pGAP forward and
3'AOX) to determine positive clones. PCR screening of 10 Pichia pastoris strains transformed with
pGAPZαA/α1AT plasmid. The presence of the specific α1AT −1600 bp PCR amplicon was detected by 1%
agarose gel electrophoresis (ethidium bromide staining), confirming the insertion of pGAPZ αA/α1AT
plasmid to yeast genome. Lane 1–10: positive colonies of α1AT1-5 constructs, V1-5: PCR positive control
(pGAPZ αA plasmid) and X33: PCR negative control, M: molecular markers.
Figure 8 Expression analysis of constructed vectors containing different α1ATs sequences by SDS–
PAGE and western-blot. (A) 72 h after induction, supernatants were electrophoresed in 12% SDS–PAGE
and stained by Coomassie blue as follows: lane M, broad-range molecular weight marker; lanes 1, 2, 3, 4
and 5 supernatant samples of α1AT 1, 2, 3, 4 and 5, respectively. (B) Proteins were transferred onto a PVDF
membrane and identified by immunoblotting using primary and secondary commercial antibodies as
follows: lane M, schematic representation of the broad-range marker; lane 1, 2, 3, 4 and 5, supernatant of
72 h inducing culture of α1AT 1, 2, 3,4 and 5, respectively, which treated rabbit anti-AAT polyclonal
antibody and then secondary Goat anti-rabbit polyclonal antibody.
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Figure 9 Elastase inhibitory assay of the five α1AT structures. α1AT and modified derivatives were
incubated with a natural target of α1AT and monitored over 20 min. The substrate is a BODIPY-FL-labeled
DQ elastin conjugate that is highly labeled so that the fluorescence signal is quenched until enzymatic
digestion yields highly fluorescent fragments. Since DQ elastin is digested by elastase, the inhibition of
elastase activity by α1AT can be determined.
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in vitro. The absence or inefficient function of α1AT in the lungs leads to uncon-
trolled function of elastase and elastin breakdown, resulting in respiratory prob-
lems such as COPD and emphysema [3-5]. Association between α1AT and a
number of diseases including asthma, rheumatoid arthritis, anterior uveitis and sys-
temic lupus erythematosus suggests that α1AT is not only an anti-inflammatory pro-
tein but also an immune system regulator [8-10]. α1AT regulates lymphocyte
proliferation and cytotoxicity, mediates monocyte and neutrophil functions. Besides,
researchers have shown that the protease-antiprotease imbalance is an important fac-
tor in the pathogenesis of COPD and other pulmonary diseases, such as bronchitis.
COPD is one of the most important causes of irreversible lung damage and thus the
fourth most common cause of death in the U.S. In this process, exogenous proteolytic
enzymes lead to lung damage. Besides different physiological roles of α1AT including
the control of insulin secretion, antiprotease activity, protecting β-cells against
cytokine-induced apoptosis, acting as an anti-inflammation compound [14-16], it is
also regarded as an antiapoptotic factor in lung epithelial cells [11]. A recent study
has shown that α1AT can slow down the loss of insulin producing cells in diabetic pa-
tients who are at the early stages of disease. This study which is in phase ІІ of clinical
trials demonstrates the effect of α1AT in preservation of β-cells' function [18,19].
Therefore, only with appropriate and adequate concentrations of α1AT the lungs'
correct function can be maintained.
One of the treatment strategies for optimum function of α1AT in inflammation is the
replacement therapy using intravenous infusion. In the infusion form only 10%-15% of
α1AT reach the target organ. Another possible treatment strategy is by airway delivery.
In this form of treatment not only the aerosolized α1AT reach directly the target organ,
but also prevent accumulation of excess drug in blood and therefore much lower
amount of drug is require [18,29]. Furthermore, in addition to the development and
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nanoparticles for pulmonary delivery are also under investigations.
During drug delivery, especially protein-based ones, the size of the protein has the
major role with regard to its packaging and delivery. In other words, the smaller the
protein size, its packaging, stability and delivery becomes more convenient. Protein
length from N-terminal was reduced to produce a smaller molecule which has the same
and even higher inhibitory activity as the native α1AT. Previous studies have shown
that the two methionine residues 351 and 358, and in sever conditions methionine 226
are susceptible to oxidation. Oxidation of methionine 358 leads the loss of anti-elastase
activity of α1AT. The other methionine residue (Met351) is also as susceptible to oxida-
tion and anti-elastase activity loss as Met358 [23,24].
Therefore, five different α1AT structures with different glycosylation patterns and mo-
lecular weights were constructed base of theoretical studies. Beside, each α1AT structures
were subjected to three or five different site directed mutagenesis at the same time for both
thermal and oxidative inactivation stability. Inhibitory properties of each α1AT constructs
were investigated through Elastase Inhibitory Concentration (EIC).
In this study, site directed mutations in α1AT, produce an active, lower molecular
weight, resistant to oxidation and thermal inactivation, with an appropriate half life and
unglycosylated protein in Pichia Pastoris as a host. In this study we showed that muta-
tions and engineering of the protein molecule, lead to an improvement in inhibitory
function. Furthermore, a protein with a less molecular weight and immunogenicity
which is suitable for drug packaging and targeting to the lung which is the site of
α1AT's action was produce. Molecular dynamic studies showed that deletion of the first
alpha-helix from N-terminal sequence have no effect on α1AT inhibitory function.
Therefore a reduction of 7 kDa in molecular weight of α1AT, 5 kDa contributing to
amino acids weight and approximating 2 kDa to the first carbohydrate chain, was
resulted.
Before entering the experimental phase of studies, the effect of eliminating the first
46 amino acids from the N-terminal region, on protein structure was investigated using
MD simulation. The native and truncated structures were modeled and the results of
the theoretical studies showed no meaningful differences between the properties of
these proteins. Results from the dynamic simulations of the molecular models and their
interactions with neutrophil elastase showed different interaction energy. The docking
energy for the α1AT 2 is less negative which shows better interaction with neutrophil
elastase. These findings provided the basis for the experimental phase of the study in
which sequences from the five α1AT constructs were inserted into the expression vec-
tor pGAPZα. α1ATs were expressed in the yeast Pichia pastoris (P. pastoris) in a secre-
tary manner and under GAP promoter transformed into Pichia pastoris. Thus,
experimental studies were carried out to produce recombinant proteins. The level of
expression and the functions of the native and truncated proteins were compared. Protein
inhibitory activity was investigated through EIC (elastase inhibitory capacity) Results show
that all five constructs have a good elastase inhibitory function, although, α1AT 2 has the
highest inhibitory activity even more than the native α1AT.
In conclusion, a recombinant and truncated protein with oxidative resistance and with-
out the two main glycosylation chains were obtained which do not effect the inhibitory ac-
tivity of the α1AT2. The results have important influence in pulmonary drug delivery.
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